Efficacy of Clobazam in Treating Lennox-Gastaut Syndrome: Insights and Clinical Outcomes

DESCRIPTION

This article explores the role of clobazam (CLB), an effective antiepileptic drug (AED), in the management of Lennox-Gastaut syndrome (LGS). It reviews clinical studies and findings shared by the American Epilepsy Society (AES) regarding the effectiveness of CLB compared to placebo (PBO) treatments and other medications such as felbamate (FBM) and topiramate (TPM). The evaluation considers FDA approvals, safety profiles, and how clobazam fits into the treatment landscape for patients suffering from LGS.

Download

1 / 25

May 14, 2026

Télécharger la présentation

Efficacy of Clobazam in Treating Lennox-Gastaut Syndrome: Insights and Clinical Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Abbreviations • AED antiepileptic drug • AES American Epilepsy Society • BZP benzodiazepine • CLB clobazam • CONTAINClObazam in PatieNTs with Lennox-Gastaut SyNdrome • FBM felbamate • FDA Food and Drug Administration • LGS Lennox-Gastaut syndrome • LTG lamotrigine • PBO placebo • RUF rufinamide • TPM topiramate • VPA valproate